Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial

2013 American Heart Journal 238 citations

Abstract

LEADER commenced in September 2010, and enrollment concluded in April 2012. There were 9,340 patients enrolled at 410 sites in 32 countries. The mean age of patients was 64.3 ± 7.2 years, 64.3% were men, and mean body mass index was 32.5 ± 6.3 kg/m2. There were 7,592 (81.3%) patients with prior CVD and 1,748 (18.7%) who were high risk but without prior CVD. It is expected that LEADER will provide conclusive data regarding the cardiovascular safety of liraglutide relative to the current standard of usual care for a global population of patients with T2DM.

Keywords

MedicineLiraglutideMyocardial infarctionDiabetes mellitusInternal medicineStroke (engine)PlaceboClinical endpointType 2 diabetesBody mass indexRandomized controlled trialHeart failureEndocrinology

Affiliated Institutions

Related Publications

Publication Info

Year
2013
Type
article
Volume
166
Issue
5
Pages
823-830.e5
Citations
238
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

238
OpenAlex

Cite This

Steven P. Marso, Neil R Poulter, Steven E. Nissen et al. (2013). Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial. American Heart Journal , 166 (5) , 823-830.e5. https://doi.org/10.1016/j.ahj.2013.07.012

Identifiers

DOI
10.1016/j.ahj.2013.07.012